Drugs / M2RLAB 001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07052513 | Dec 2025 → Jun 2027 expected | acute kidney injury | M2RLAB SL | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | M2RLAB 001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07052513 ↗ |
| Route | Intravenous | “Intravenous infusion of M2RLAB 001” NCT07052513 ↗ |